Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Osborne V, Davies M, Lane S, Evans A, et al. Drug Saf 2020;43:809-821.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Osborne V, Davies M, Lane S, Evans A, et al. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Drug Saf 2020;43:809-821.
PMID: 32578156